Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (299 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

299 publications

Palbociclib (PD-0332991) HCl Chemical Structure

CAS No. 827022-32-2

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 299 publications

Nat Med, 2021, 10.1038/s41591-020-01168-7

PubMed: 33462444 ( click the link to review the publication )

Nature, 2020, 17

PubMed: 32555459 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Cell, 2020, 16;181(2):424-441.e21.

PubMed: 32234521 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(2):277

PubMed: 29395057 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Genome Biol, 2021, 22(1):176

PubMed: 34108027 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3356

PubMed: 34099663 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458

PubMed: 34103301 ( click the link to review the publication )

J Cell Biol, 2021, 220(8)e202009147

PubMed: 34037657 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108636

PubMed: 33472061 ( click the link to review the publication )

Elife, 2021, 10e61797

PubMed: 33522487 ( click the link to review the publication )
Elife, 2021, 10e65234

PubMed: 33983115 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )

Cancers (Basel), 2021, 13(10)2396

PubMed: 34063457 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):54

PubMed: 33723248 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

Cancer Discov, 2021, candisc.1114.2020

PubMed: 33879449 ( click the link to review the publication )

Neoplasia, 2021, 23(1):140-148

PubMed: 33316538 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044

PubMed: 33865884 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(4):651-666

PubMed: 33443106 ( click the link to review the publication )

Cancer Biol Med, 2021, 18(1):227-244

PubMed: 33628597 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4559

PubMed: 33925399 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(6)2915

PubMed: 33805656 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Breast Cancer Res Treat, 2021, 186(3):677-686

PubMed: 33599863 ( click the link to review the publication )

Clin Genitourin Cancer, 2021, S1558-7673(21)00029-X

PubMed: 33676835 ( click the link to review the publication )

J Pers Med, 2021, 11(4)292

PubMed: 33921303 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)524

PubMed: 33572972 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):26

PubMed: 33602273 ( click the link to review the publication )

Anal Chem, 2021, 93(5):3052-3060

PubMed: 33502178 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108744

PubMed: 33596421 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5305

PubMed: 33082317 ( click the link to review the publication )
Nat Commun, 2020, 2;11(1):2760

PubMed: 32488085 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-0943-5

PubMed: 32591645 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )

J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3215-3221

PubMed: 32606000 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cell Rep, 2020, 33(9):108449

PubMed: 33264622 ( click the link to review the publication )

Cell Rep, 2020, 32(10):108102

PubMed: 32905768 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Haematologica, 2020, haematol.2020.249177

PubMed: 32855276 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):262

PubMed: 33243298 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):87

PubMed: 32787886 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):754

PubMed: 32934219 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )
Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2221-2232

PubMed: 32747423 ( click the link to review the publication )

Front Oncol, 2020, 10:563249

PubMed: 33072590 ( click the link to review the publication )

J Cell Sci, 2020, 133(18)jcs247940

PubMed: 32878943 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Sci Rep, 2020, 10(1):18489

PubMed: 33116269 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:280

PubMed: 32624705 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:501

PubMed: 33061853 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):941

PubMed: 32998722 ( click the link to review the publication )

Open Biol, 2020, 10(10):200200

PubMed: 33052073 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):89

PubMed: 32795346 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0236298

PubMed: 32701996 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):262

PubMed: 33243298 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01403-y

PubMed: 32712628 ( click the link to review the publication )

J Pathol, 2020, e5493

PubMed: 32558936 ( click the link to review the publication )
Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

Clin Transl Med, 2020, 10(1):182-198

PubMed: 32508030 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa653

PubMed: 32761127 ( click the link to review the publication )

Anticancer Res, 2020, 40(12):6699-6712

PubMed: 33288563 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e11031

PubMed: 31512803 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

PLoS Biol, 2019, 17(8):e3000203

PubMed: 31430272 ( click the link to review the publication )

PLoS Biol, 2019, 17(4):e3000228

PubMed: 31039152 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(25):4962-4976

PubMed: 30833638 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Sci Signal, 2019, 12(601):eaay0482

PubMed: 31575731 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )
J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2019, 316(1):E135-E144

PubMed: 30512986 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )
Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:11107-11117

PubMed: 31908479 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31399419 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )
Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(6):1597-1609

PubMed: 30089269 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(13):1685-1698

PubMed: 29335521 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0206368

PubMed: 30383785 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

SSRN, 2018, 10.2139/ssrn.3188455

PubMed: None ( click the link to review the publication )

Oncotarget, 2018, 9(79):34990-34995

PubMed: 30405888 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )
Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

J Mol Cell Biol, 2017, 1;9(2):154-165

PubMed: 27927748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Oncogenesis, 2017,

PubMed: 28504693 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1535

PubMed: 28484242 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )
PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83432-83445

PubMed: 29137354 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1PO.17.00140

PubMed: 32913968 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84743-84760

PubMed: 29156680 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55319-55331

PubMed: 28903422 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

EMBO Rep, 2016, 17(3):414-27

PubMed: 26882548 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2419

PubMed: 27735950 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:20376

PubMed: 26847534 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

BMC Syst Biol, 2016, 10(1):73

PubMed: 27515956 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Sci Rep, 2015, 5:14391

PubMed: 26399741 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(9):1506-22

PubMed: 25733683 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140243

PubMed: 26460486 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )
Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Oncotarget, 2015, 6(29):28057-70

PubMed: 26356814 ( click the link to review the publication )

Blood, 2014, 3;124(1):13-23

PubMed: 24764564 ( click the link to review the publication )

Cancer Res, 2014, 74(6):1739-51

PubMed: 24473065 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

J Virol, 2013, 87(8):4623-41

PubMed: 23408614 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )
Cell Cycle, 2013, 12(23):3689-701

PubMed: 24189531 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78641

PubMed: 24265703 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cancer Prev Res (Phila), 2012, 5(6):810-21

PubMed: 22508966 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Clin Cancer Res, 2011, 1;17(13):4513-22

PubMed: 21593195 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	MXHLbY5ie2ViQYPzZZk>		MYmyOEBp		M{naPGlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh\|ryP	M{T5PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
COLO205	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVy3NkBp		MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODN4IN88US=>	M1LFV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSxNVA{Lz5{NE[0NVExOzxxYU6=
U937	NFXtXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGDCfIY4OiCq		NIfyWZNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO	NIG4Z409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
MOLM13	NXrv[HJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUfrXoR[PzJiaB?=		NXu3NWNHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>?	MmnVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MOLM13	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIjNcpc4OiCq		M3;0XWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sgd49z[W[nbnniMZJme2m\|dHHueEBpfW2jbjDNU2xOOTNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkC5OkDPxE1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2MUGwN{c,OjR4NEGxNFM9N2F-
MDA-MB-435	NX3ET2IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4TqZlI1KGh?		MnzuTWM2OD1yLkG2JO69VQ>?	NYfBb4s4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFE5OzFpPkG1PFAyQDNzPD;hQi=>
K562	M4TQN2N6fG:2b4jpZ{BCe3OjeR?=		MWK5OkBp	NGrHNGlFVVOR	MlHPTWM2OD1{IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
DU145	NYDJNHJSS3m2b4TvfIlkKEG\|c3H5		M1XLblk3KGh?	MWTEUXNQ	MXXJR\|UxRTdwNTFOwG0>	NIHaXo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MDA-MB-231	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHySXMxOSEQvF2=	NUXIemZEOjRiaB?=	NFz1OXFFVVOR	NWjm[GNES2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm	M3TRTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEG3OVY3Lz5{NESxO\|U3PjxxYU6=
MCF7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGX3b4EyKM7:TR?=	MkDpNlQhcA>?	NYXiZWdOTE2VTx?=	M1\yU2NmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=>	NGS3RYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MCF7	MVPLbY5ie2ViQYPzZZk>	NHjsTIE2KM7:TR?=	MnPYNlQhcA>?	MWrEUXNQ	NGLwXIJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG\|dH;tZUBxcG:\|cHjvdplt[XSrb36gZZQhW2W{N{iw	NHfMPFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MDA-MB-231	M2LibGtqdmG\|ZTDBd5NigQ>?	MXW1JO69VQ>?	MYWyOEBp	Ml\FSG1UVw>?	MkPNTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=	Mn7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MDA-MB-231	Ml3ESpVv[3Srb36gRZN{[Xl?	NELhflgyNTFyIN88US=>	M{jzcFI1KGh?	MWHEUXNQ	NELicHZld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=	NHjyW\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxO\|U3Pid-MkS0NVc2PjZ:L3G+
MCF7	MUjGeY5kfGmxbjDBd5NigQ>?	NVrzOFkxOS1zMDFOwG0>	M4m1VlI1KGh?	MkDQSG1UVw>?	NUP1Wnhm\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl	MnzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
MDA-MB-231	MlT6SpVv[3Srb36gRZN{[Xl?	MU[wMlUuOSEQvF2=	NFv4eII1QCCq	M3nseGROW09?	M{nzZohieyCwbzDD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
MCF7	Ml71SpVv[3Srb36gRZN{[Xl?	MVuwMlUuOSEQvF2=	MVi0PEBp	NXjxbWZzTE2VTx?=	NXjYdGFycGG\|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
MOLM13	NFPhTo1ETEt2IHnubIljcXSrb36gZZN{[Xl?		Moq0NlQhcA>?		MkXBTWM2OCB;IECuNFEyKM7:TR?=	NVjrNJp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
A2780	NWDxcmV1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIrvOZc4OiCq		NF\PUYVIUTVyIE2gNE4xOzJizszN	NX7UPIlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
COLO205	NVW3SplnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NVfaVIVpPzJiaB?=		NWDpOnNiUUN3MDC9JFAvODN4IN88US=>	MoLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MV4-11	M2rx[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXu3NkBp		MkTFS2k2OCB;IECuNFUh\|ryP	NGj3S\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
MOLM13	MlqxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUD3c3JFPzJiaB?=		MXvHTVUxKD1iMD6wOlIh\|ryP	NX3LPIJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
NB4	MlzMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MorZO\|IhcA>?		MorqS2k2OCB;IECuNFY3KM7:TR?=	Mo\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
PC3	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXT5RWVvPzJiaB?=		NVmybGJTT0l3MDC9JFAvODdzIN88US=>	M1XVeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
MOLM13	MnjkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MXi3NkBp		MVHJR\|UxKD1iMD6wPVYh\|ryP	NGXWXVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
MOLM13	NGq2[pFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MojIO\|IhcA>?		M4nvOmlEPTBiPTCwMlA6PiEQvF2=	NVnid4M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFEyODNpPkK0OlQyOTB\|PD;hQi=>
MDA-MB-453	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		NHPMfnM1QCCq		MkTmTWM2OCB;IECuNVM4KM7:TR?=	M2DSTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NES4PVE{Lz5{N{S0PFkyOzxxYU6=
U937	Mn3ZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M2HxeFczKGh?		MUfJR\|UxKD1iMD6xOEDPxE1?	NHv3dZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0NVExOyd-MkS2OFEyODN:L3G+
MDA-MB-435	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NXf2W4dnOjRiaB?=		NFPWdmlKSzVyIE2gNE4yPiEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNUW3NUc,OjZzMUW1O\|E9N2F-
MCF7	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=		NWLNXpZ4PDhiaB?=		NF7zT\|lKSzVyIE2gNE4zPCEQvF2=	MlfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2NEi5NVMoRjJ5NES4PVE{RC:jPh?=
MDA-MB-453	MlrSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHjXZlQ4OiCq		MXnHTVUxKD1iMD6zNlYh\|ryP	NIfKW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
MCF7	NGLoc5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHXsW2U4OiCq		MXnHTVUxKD1iMD61OVch\|ryP	NHLIWXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
MDA-MB-231	NHWwToJEgXSxdH;4bYNqfHliYYPzZZk>		MV20PEBp		NYHObY44UUN3MDC9JFAvPThizszN	NVj1d3BNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0OFg6OTNpPkK3OFQ5QTF\|PD;hQi=>
M229	NIPWfmxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoC3O\|IhcA>?		NVG5ZnB5T0l3MDC9JFEvOjJizszN	M3fk[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
M238	M4nHcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEnme3o4OiCq		NG\FbldIUTVyIE2gNU46PyEQvF2=	NVTldHZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixOVYyOTFpPkK4NVU3OTFzPD;hQi=>
M249	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV65fZpyPzJiaB?=		M{DpNmdKPTBiPTCxMlk6KM7:TR?=	NFftdXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
K562	M{e2XGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXy5OkBp		Mmj3TWM2OCB;IEKg{txO	Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUe1OlYoRjJ2NEG3OVY3RC:jPh?=
M249R	M1v0eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWXSR4VFPzJiaB?=		MXfHTVUxKD1iMj65OkDPxE1?	M{jzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUW2NVEyLz5{OEG1OlEyOTxxYU6=
MOLM13	MYTGUHQ{KGmwaHnibZRqd25iYYPzZZk>		MViyOEBp		NYHjelF4UUN3MDC9JFMh\|ryP	Mn;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEGxNFMoRjJ2NkSxNVA{RC:jPh?=
MDA-MB-468	NFvHeI9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NX;KbWFtOjRiaB?=		NUXiNpB6UUN3MDC9JFMh\|ryP	NGfT[VE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOVU4OSd-Mk[xNVU2PzF:L3G+
C4-2B	NXLIenNGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{nJN\|czKGh?		M{XQSmdKPTBiPTC0MlE2KM7:TR?=	NH;QZVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
DU145	NYTPS5d2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVy3NkBp		M{mw[WdKPTBiPTC1Mlc6OiEQvF2=	MkSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
MDA-MB-468	M1;lZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MknKO\|IhcA>?		MofVS2k2OCB;IEWuPVYh\|ryP	NEn3NGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
BPH1	NFPPc2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MljDO\|IhcA>?		MXfHTVUxKD1iNz60OFIh\|ryP	MnzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzNU[xNVEoRjJ6MUW2NVEyRC:jPh?=
DU145	NG\HSZhEgXSxdH;4bYNqfHliYYPzZZk>		MXy5OkBp		NXTzVHFrUUN3MDC9JFcvPSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzN{W2Okc,OjR2MUe1OlY9N2F-
MRC5	NH7UOFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYe3NkBp		MoCxS2k2OCB;IEGwJO69VQ>?	NFj6XVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG1OlEyOSd-MkixOVYyOTF:L3G+
697	M4TjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH36XG5KSzVyPUG0PE4{QCCwTR?=	MnfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmi1TWM2OD17Nj6wOEBvVQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB69	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzOToZQUUN3ME2xOlEvQCCwTR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EoL-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH2zU45KSzVyPUG4O{4zPiCwTR?=	NFvlXlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BHT-101	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LzV2lEPTB;MUm4MlI2KG6P	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-NEP-1	NInqPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\Eb2lEPTB;MkKwMlAzKG6P	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MHH-NB-11	NWCzeZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPscldKSzVyPUKyNE4yQSCwTR?=	M3\LOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
AsPC-1	NVLyRng1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFi4eoxKSzVyPUK1Nk42OyCwTR?=	MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES1	M1\yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfGS4dsUUN3ME2yOVYvOjVibl2=	M2HrSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LAMA-84	M13iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vzXmlEPTB;MkW4MlE6KG6P	M37MOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MOLT-16	NX7UZpR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrGW3JkUUN3ME2yOVgvPDlibl2=	Mlz6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES7	NYHpZ4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml30TWM2OD1{N{OuNFkhdk1?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KY821	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTNzND6xJI5O	M3LXdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
RT-112	NVewTItKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4O4ZmlEPTB;M{KxMlA2KG6P	NVv1eWxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HL-60	NWLnS2ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX22ZVluUUN3ME2zOFAvPjZibl2=	NETVc2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MOLT-4	NFLxXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzObJRKSzVyPUO0OU4yOyCwTR?=	NYLOO\|N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KARPAS-45	NWTUboZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlniTWM2OD1\|N{[uNVYhdk1?	NWr6WINvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-N-AS	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDkTWM2OD1\|OEeuPFMhdk1?	NYLsOHNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CTB-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTRyNT6wNkBvVQ>?	MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NKM-1	M2PJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojFTWM2OD12MUGuPFkhdk1?	NX25d3UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HTC-C3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7LTWM2OD12M{KuPVUhdk1?	MlG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BE-13	M2nsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fjeGlEPTB;NES0MlI4KG6P	NWTtUVc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KOSC-2	NEPvVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\GfGlEPTB;NE[2Mlkhdk1?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB14	NIO2WldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M124OmlEPTB;NEizMlU5KG6P	NEHC[3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CAL-27	NFz5RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPIZVBGUUN3ME20PVQvPTlibl2=	MnvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
H9	NIfyN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjmUnZZUUN3ME20PVUvPDNibl2=	NELTUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
RS4-11	NEfHOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XPbWlEPTB;NUC0Mlc{KG6P	M2PoWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
PA-1	NF3HSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTVyOT64OkBvVQ>?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MV-4-11	NUfBbnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTVzMz64OUBvVQ>?	M1rrUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OS-RC-2	Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTV{MT62NkBvVQ>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RPMI-8226	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTV{Nj64OkBvVQ>?	NY\3R2ZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HGC-27	NHXkfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnjcoY2UUN3ME21OlQvQTlibl2=	M4D3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CHP-212	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLVTWM2OD13OUOuOVkhdk1?	Mn3LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NB10	NEXHcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X3[GlEPTB;NUm5MlE5KG6P	NUPFUXA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HH	NWLsXmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTV7OT60N{BvVQ>?	NXHme4hxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EW-16	M2LiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVu4ZYJlUUN3ME22NFMvPTJibl2=	NIrkSlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
ES8	NFfEU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrPN3d3UUN3ME22NFUvOjFibl2=	M4rRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HAL-01	M3ryO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXMTWM2OD14MEWuOlchdk1?	M3nlT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
A204	NVjubmRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTBfZN{UUN3ME22N\|MvQTFibl2=	NF\5XWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MHH-PREB-1	Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInRbJlKSzVyPU[zOk46QSCwTR?=	MnLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EM-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkD2TWM2OD14NUCuOlQhdk1?	MmLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BV-173	NITRNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PWSWlEPTB;NkWyMlQ5KG6P	NES0TWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
ONS-76	NULacVUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTZ5Nz64NkBvVQ>?	NXThemhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KM-H2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHpWG9KSzVyPU[5OU42PCCwTR?=	NHTsOXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-263MG	NFHYOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfudYxKSzVyPUexO{4yOiCwTR?=	M4DWflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
ES3	NI\qdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTd{OD65N{BvVQ>?	NX;MSJpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	M{GyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjZVHRUUUN3ME23N\|IvOjdibl2=	MlPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NBsusSR	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlX6TWM2OD15NEKuPVkhdk1?	M4XLT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H520	NHPW[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTd2Nj61NkBvVQ>?	MmDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES5	M3LqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHTTWM2OD15NUKuPEBvVQ>?	Mk\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
T-24	NVW0SJl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILPZ5JKSzVyPUe3PE44OSCwTR?=	M2jnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW962	M4G1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjXNoZLUUN3ME24NFgvPjNibl2=	M3fwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
EW-3	NWTYO2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7jTWM2OD16MEiuO\|Yhdk1?	NUew[Y54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
RXF393	NUH2eFQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFizZYVKSzVyPUixNk44QSCwTR?=	NIqzVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
U251	NGnSbJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jhZmlEPTB;OEGzMlg5KG6P	NYfiUoFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CAMA-1	MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnIWZlKSzVyPUizN{46PCCwTR?=	M4HNbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
JVM-3	M{KyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTh3MT63PEBvVQ>?	M2fIPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
COLO-800	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\TSml[UUN3ME24PVcvPzhibl2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
OVCAR-5	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFm2cY9KSzVyPUmwNE4yKG6P	NUnGXVVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LB1047-RCC	M3fpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;JTWM2OD17MkeuOVYhdk1?	M1vlWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW954	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTl{OT60NUBvVQ>?	MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NWnLXZA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfLNpZqUUN3ME25N\|YvODZibl2=	M1;Ld\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Mewo	MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HwbWlEPTB;OUO2MlYhdk1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H1770	M3HsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e5TWlEPTB;OUSwMlU2KG6P	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HO-1-N-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrMXmQ1UUN3ME25OlIvQDFibl2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HSC-3	M4\McGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfuTWM2OD17Nk[uOFghdk1?	M2S4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TYK-nu	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDob4FKSzVyPUm5PE4zPSCwTR?=	NF24NIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KYSE-150	NIPTZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHlZnlKSzVyPUGuNFAxPzZizszN	M37JdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SN12C	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwMEC4O\|Uh\|ryP	NFvsWW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MOLT-13	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DvbWlEPTB;MT6wNVQzOSEQvF2=	MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TE-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;wTWM2OD1zLkC0PFEzKM7:TR?=	M2HkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
DB	M1jsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX5UotKSzVyPUGuNFczPzNizszN	NH6zfIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CAL-39	NYTMdXl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4ntSWlEPTB;MT6wO\|UzOiEQvF2=	MkDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A3-KAW	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfJXYpKSzVyPUGuNFg1ODhizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CHP-134	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFwMUG4NFch\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TGW	NV\HbIF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HxUWlEPTB;MT6xNlM6PSEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NUnlTm9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\EUWVNUUN3ME2xMlE{OTN2IN88US=>	Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7pU5BKSzVyPUGuNVY{PTRizszN	M1nae\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
CGTH-W-1	NILTPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTWeGlzUUN3ME2xMlE4OTh4IN88US=>	NEXwSZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MHH-ES-1	NX3XVIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofJTWM2OD1zLkG3PVg3KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LB2241-RCC	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3q4PWlEPTB;MT6xPFYzKM7:TR?=	NHvXb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
ML-2	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7XTWM2OD1zLkKwO\|M1KM7:TR?=	MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
COR-L23	Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjZTZhxUUN3ME2xMlIzQTN\|IN88US=>	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
BFTC-905	NV30XYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELFNllKSzVyPUGuNlQzPjdizszN	M1HBeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Hs-578-T	M{f1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHpfXhKUUN3ME2xMlI2QDF5IN88US=>	MoTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KG-1	M{\oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljQTWM2OD1zLkK2Olg3KM7:TR?=	NFzHSYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnuzTWM2OD1zLkK5N\|M5KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A549	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjxXoRKSzVyPUGuNlk{QTlizszN	NFrGSoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
COLO-741	NEnSOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFwM{KwPFkh\|ryP	MlXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
PC-3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHrWZZKSzVyPUGuN\|UzOjFizszN	M162UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HOS	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:zTWM2OD1zLkO1Nlk3KM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HT-1080	NYLNUGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\lTWM2OD1zLkO3OVE6KM7:TR?=	NIDGdmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TE-8	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmOxTWM2OD1zLkSxO\|c1KM7:TR?=	NFfwUYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BHY	NH3pO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP5bnJ[UUN3ME2xMlQ3QTJ\|IN88US=>	NXGyW2N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BB65-RCC	NV;u[XZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwNUC1Nlgh\|ryP	MlTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HN	NVjyTZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTMVGtnUUN3ME2xMlU1ODdzIN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H441	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;SR4NKSzVyPUGuOVQ6ODdizszN	NWnETnVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
RPMI-8866	NXf6bmRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\6OoFqUUN3ME2xMlU5PTB5IN88US=>	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAL-62	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFwNkC4OlIh\|ryP	NEXCZ2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MG-63	NXH6N3o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvORWRKSzVyPUGuOlE5OTNizszN	M4qxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SK-LU-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTFwNkKxOVIh\|ryP	M2nLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
BCPAP	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPiTWM2OD1zLk[2OFU4KM7:TR?=	M4q0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
22RV1	NGjzS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3EdlR2UUN3ME2xMlY4QDR\|IN88US=>	MnnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
T47D	MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXNW4lOUUN3ME2xMlY5ODZzIN88US=>	M1LB[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MSTO-211H	NVfmZoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLCb\|lKSzVyPUGuOlk3ODNizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
DEL	M{WybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTMTnhSUUN3ME2xMlcxOjd\|IN88US=>	M1LPWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
H4	NFrQWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXQNZlYUUN3ME2xMlc{OjF{IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-51	NF\tTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojQTWM2OD1zLke0PFU2KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ABC-1	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7QTWM2OD1zLke4OVgzKM7:TR?=	NXriclJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MZ2-MEL	NVH4c291T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnC[mtKSzVyPUGuO\|k2PDJizszN	MnH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
YKG-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\RS5ZKSzVyPUGuPFExPjFizszN	NXLufmdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KM12	M4LiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofoTWM2OD1zLkixOlAzKM7:TR?=	NICxTZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
L-363	NIXKNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFwOEe0NVIh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KU812	NHrYdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfo[3pKSzVyPUGuPFkzQDJizszN	NGXYS2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LOXIMVI	NUO0d\|lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfVdZFMUUN3ME2xMlkyOjJ6IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
G-401	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjhb2dKSzVyPUGuPVI1OjhizszN	NXf5bZVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW780	NHzhO\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTx[pVKSzVyPUGuPVYzPDZizszN	M2TLPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SW872	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3XO3JFUUN3ME2xMlk5OzNizszN	Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NB7	M2n6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFwOUmzNlMh\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
T98G	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLMTWM2OD1{LkCwOlY3KM7:TR?=	Ml;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SW1710	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTiSlBKSzVyPUKuNFY6PDVizszN	NWK2[VZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1573	NEC4NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUmyXWRVUUN3ME2yMlA4Ojl6IN88US=>	MkXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KE-37	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJwMEi5OVEh\|ryP	MkPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
786-0	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13QcGlEPTB;Mj6xOVQ{QSEQvF2=	NHPKc\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SAS	M{C5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJwMkCzO\|Qh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-54	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHyycm5KSzVyPUKuNlA1OTNizszN	NEnPUmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SF268	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2H2PWlEPTB;Mj6yN\|EzOiEQvF2=	NWrqN2VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SW620	NWfpWZRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWGzepRNUUN3ME2yMlI3OTZ7IN88US=>	M{DnTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MN-60	NYDZ[IplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPUSIc2UUN3ME2yMlMyODZizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EFO-27	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6xTWM2OD1{LkOyNFU5KM7:TR?=	NU\PRlB2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H747	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzt[ow3UUN3ME2yMlMzOTl7IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HCC2218	M3TGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofkTWM2OD1{LkO1N\|c1KM7:TR?=	NGnIO4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MIA-PaCa-2	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHYTWM2OD1{LkO2OFM4KM7:TR?=	MmLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SJSA-1	NHPndFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJwM{e3PVYh\|ryP	NGXueVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
RKO	NYHjXlBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFS5OXpKSzVyPUKuN\|g1QTZizszN	NITLNmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NB6	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HFR2lEPTB;Mj60NFM4PCEQvF2=	Mmj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES4	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJwNEW0NlIh\|ryP	NFLEV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EGI-1	NHzodGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTJwNE[4PFMh\|ryP	NV\tcVhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CTV-1	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUewdXRkUUN3ME2yMlUzPzd\|IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H1355	NG\DZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rybWlEPTB;Mj61OVk2OSEQvF2=	NGHPbII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GT3TKB	NWi4NmNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTJwNUmxPVkh\|ryP	NIDBOJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-HEP-1	M3nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTJwNUmyOlYh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
GAMG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPTV2gxUUN3ME2yMlU6Ozl2IN88US=>	Moe5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SK-MES-1	NVvpW5hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1KzVGlEPTB;Mj62NVgxOyEQvF2=	NWK0dZNHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
RO82-W-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHhTWM2OD1{Lk[yNFU4KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ECC10	NE\MTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;pdWY4UUN3ME2yMlcxOjB4IN88US=>	NX76fZlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MCF7	M3jYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlP6TWM2OD1{LkexOFY1KM7:TR?=	NE\VVGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-283MED	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rDV2lEPTB;Mj63NlQ{KM7:TR?=	NI\ZWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
RPMI-7951	NYq3TYJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv1cXlqUUN3ME2yMlc2Pjl2IN88US=>	NF7IZlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJwN{ewPVkh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KGN	NEXU[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojXTWM2OD1{LkixPFg1KM7:TR?=	M3yzNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NUGC-3	NWDXe\|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTGUnN{UUN3ME2yMlgzPTB3IN88US=>	NYW3bphwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H292	NEftV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XDNGlEPTB;Mj64OVA2OyEQvF2=	NGjyeoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Becker	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGL2N\|RKSzVyPUKuPVU5OzJizszN	NUTyfXFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1299	NX3TcXpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LvcmlEPTB;Mz6wOVI3OyEQvF2=	NWPaRYlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ETK-1	M{PueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXRTWM2OD1\|LkC1OFMh\|ryP	NEKxUFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
TK10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTNwMkCxOlUh\|ryP	NHvoPGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
VMRC-RCZ	NFL3S5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNwM{[0PFgh\|ryP	NYfFeJE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
YH-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTpVHdGUUN3ME2zMlQ1ODd7IN88US=>	NWHFbXJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
DU-145	NFXa[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFi2[ZBKSzVyPUOuOFYzPjlizszN	Mn72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SW1088	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUX2V3VsUUN3ME2zMlQ4PDdizszN	Mk\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HOP-92	M1rWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm5dFYzUUN3ME2zMlUxOzR{IN88US=>	MkeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KP-N-YS	M3juc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXXdJdKSzVyPUOuOlIyOzlizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H460	NVPOfI5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIX4OlhKSzVyPUOuOlY4OyEQvF2=	M{DnT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
U-2-OS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PDPGlEPTB;Mz63NlU{PSEQvF2=	M2HjXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
A101D	NYjhRpROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTNwN{[5N\|Yh\|ryP	M1rl[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-231	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWj6eW12UUN3ME2zMlgyQTVzIN88US=>	MkPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
IST-MES1	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTURY1KSzVyPUOuPFMzKM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
COR-L105	NEnSS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrQdFNKSzVyPUSuNFE5KM7:TR?=	M1\xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1437	M4DEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTRwMEKzNFIh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-85-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfaTWM2OD12LkCyOFYyKM7:TR?=	NFjQfGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
MZ1-PC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3XSolXUUN3ME20MlE5PTV4IN88US=>	NFzJclQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
VM-CUB-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTRwM{GyPFQh\|ryP	MoC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CHL-1	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe0bVE6UUN3ME20MlMzOTZ7IN88US=>	M{j3bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-361	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vuVWlEPTB;ND6zN\|E2OyEQvF2=	Mn7oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H661	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTRwNUCwPVIh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EW-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPYcpl3UUN3ME20MlUzOjNzIN88US=>	NGm4b489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BEN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml[1TWM2OD12LkWyPFE2KM7:TR?=	NHPHXJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BFTC-909	M1vGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUCxVJY4UUN3ME20MlU3Ojd3IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2087	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PYOmlEPTB;ND61PFE3PCEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RVH-421	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TIWmlEPTB;ND62OlY6KM7:TR?=	M{\NS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
P30-OHK	NHL0XoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPVVVJKSzVyPUSuOlgxODhizszN	NEDRWY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H28	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnO3TWM2OD12LkixOlYyKM7:TR?=	MlXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
ES6	M{n3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTRwOEOwNVYh\|ryP	NWTr[YdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
769-P	NEfmb\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHITWM2OD12Lki1PVI3KM7:TR?=	MkL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
OE33	NXq2Vo53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fW[2lEPTB;ND64PFE3OSEQvF2=	NIixTHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SW982	NHTwVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\X[5FDUUN3ME20Mlk2ODZzIN88US=>	M3e4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
A388	NUD0bGpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPrTWM2OD13LkCyPVg{KM7:TR?=	M3fBflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
TI-73	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfHPZd3UUN3ME21MlA3OTl2IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HCT-116	NGDWV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzr[3NTUUN3ME21MlA6QDh7IN88US=>	NYL5S\|N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HuP-T3	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTVwMUi3NFkh\|ryP	NXrGTYIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
G-402	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUL1TW15UUN3ME21MlE6PDF4IN88US=>	NWW0TYU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1792	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULPTop4UUN3ME21MlI1PjJ{IN88US=>	M16y[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H209	NEfJUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHCTWM2OD13LkK1PVQzKM7:TR?=	NXXRTVc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1650	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7DXHpoUUN3ME21MlMxPjN2IN88US=>	NF;tRXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
LCLC-97TM1	NVTIeW06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DV[mlEPTB;NT6zNVgxQCEQvF2=	NETjZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
S-117	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\CZ4VOUUN3ME21MlM3QTd4IN88US=>	NFO2fIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GI-ME-N	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTVwM{m2PFEh\|ryP	NFS3XVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H2122	M4POXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjT[WRKSzVyPUWuOFk{QTdizszN	MmHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1793	NWL3XGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTVwNke1PVMh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
C2BBe1	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3j5OmlEPTB;NT63NFA5QCEQvF2=	MoPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TE-12	NFXP[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnyRllMUUN3ME21MlgxPTV4IN88US=>	NXXwWphJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LCLC-103H	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ThbWlEPTB;NT65NVch\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A673	NWnMNm45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XqOmlEPTB;NT65NVk{OiEQvF2=	NFXGSmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BB30-HNC	M1TB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zLXWlEPTB;NT65PFM3KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SF295	NYSwVphGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDLTWM2OD14LkCwOFIzKM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KU-19-19	NF\Wb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlu5TWM2OD14LkCxO\|MyKM7:TR?=	NVvyc3ZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CFPAC-1	M{Owb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TJWmlEPTB;Nj6wOFQ1OyEQvF2=	NXOzdJI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LoVo	M{TDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfRS3M2UUN3ME22MlA2ODZ\|IN88US=>	MkHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
8505C	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInEd3VKSzVyPU[uNFc2PzNizszN	NIT5blM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GMS-10	M1i5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTZwMUWwNFIh\|ryP	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Ca9-22	NG\Be\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfuNpJKSzVyPU[uNVY4OSEQvF2=	NEnjcms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
DOK	NU\ibVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTZTWM2OD14LkKyNFczKM7:TR?=	MnLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
FADU	NFrmSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfmdGVKSzVyPU[uNlYxOzlizszN	NWPCeWE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BxPC-3	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDPTWM2OD14LkK3N\|Ih\|ryP	NVT1OVYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CAL-33	NGLOOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jJVWlEPTB;Nj6yPVIxOSEQvF2=	NYizfZdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SHP-77	NV;mWYFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzITWM2OD14LkOxOVEzKM7:TR?=	Mo[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
LXF-289	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\XTWdKSzVyPU[uN\|M1PTVizszN	MlWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GB-1	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTSSpR7UUN3ME22MlM5OiEQvF2=	NYSzbo86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KS-1	NFnRV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTZwM{i0OFch\|ryP	MmS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
D-502MG	M1fLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfJ[W1IUUN3ME22MlQzOzd4IN88US=>	M1Loe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LAN-6	NXrHflBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTZwNUGwNlMh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
H-EMC-SS	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLWdJBnUUN3ME22MlU3OTR5IN88US=>	M4i0XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LC-2-ad	NGXKc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LGSWlEPTB;Nj62NFA4PiEQvF2=	NXjnbZZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1693	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfzUG5KSzVyPU[uOlIzOTVizszN	NYP4UmZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-N-FI	NF2wVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PCOWlEPTB;Nj63OVA1PCEQvF2=	NIrJcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-423MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXYW2FWUUN3ME22Mlc3OTF5IN88US=>	NXj1SYNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KNS-42	NGHmbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrNS4lKSzVyPU[uO\|gyQTdizszN	MmLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
GCT	M1Hac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFf0d\|ZKSzVyPU[uPVM5KM7:TR?=	Ml3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
DSH1	MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTdwME[zN{DPxE1?	NF3ORWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
D-247MG	M{j5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTOTWM2OD15LkC3PFgyKM7:TR?=	NIrZXVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-SNU-5	NWj4WnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTdwMUizO\|Eh\|ryP	MmWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TE-6	NX3W[Jh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTdwMkC2NFEh\|ryP	NUTubWRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NOMO-1	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLGPY5JUUN3ME23MlIzOTJ5IN88US=>	MljkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NB17	M3LnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzBeVlKSzVyPUeuN\|A{ODlizszN	NGDGV5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
EW-22	NHPSem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\YTWM2OD15LkO0N\|Q5KM7:TR?=	NV7nPJlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EW-13	NH[5R5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTdwM{WxOlIh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
DOHH-2	M3PrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTdwNESwNkDPxE1?	NV\KTpNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
TGBC1TKB	NIrqNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonYTWM2OD15LkS5PFk6KM7:TR?=	NFrpXFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GR-ST	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLkdnpKSzVyPUeuOVI2QTRizszN	Ml\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
KYSE-520	NHzpN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n3S2lEPTB;Nz61OVUyPSEQvF2=	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAPAN-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTdwNUm1NUDPxE1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HCE-4	M4rlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDrTWM2OD15Lk[yNlc6KM7:TR?=	M170SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MLMA	NXnHXZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHEPJdKSzVyPUeuOlI6PTdizszN	MnfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HT-144	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTdwNkWzOlgh\|ryP	M1rSdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KYSE-180	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTdwN{GxOlkh\|ryP	MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
TE-5	NWXwPYk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHP2VHRKSzVyPUeuPVU6PzFizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
IGROV-1	NXPxN4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTdwOUi1OVEh\|ryP	MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1581	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\rbmlEPTB;OD6wNVIh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW1990	M4T2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TWc2lEPTB;OD6wOFY2QSEQvF2=	MmPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EFM-19	NGHXe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\zTWM2OD16LkC4OVQ2KM7:TR?=	M1LLSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OGR-1	NYrwVYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTzcohOUUN3ME24MlQ{ODJ\|IN88US=>	NGHEWHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
U-118-MG	M1z1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PscWlEPTB;OD60N\|Q3OyEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-OV-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTJTWM2OD16LkS2O\|Y2KM7:TR?=	NUjI[4NHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KNS-62	NUi0WHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRThwNUG3OlEh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
GOTO	M2rrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fWWmlEPTB;OD61O\|Y{PSEQvF2=	M4HFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
8305C	NWXaTFRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRThwN{C0PFQh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RPMI-2650	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\hOG9XUUN3ME24MlcyQTV3IN88US=>	NEPibnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NEC8	M2TyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXPU4ZNUUN3ME24Mlc1OzB5IN88US=>	NWTiNodTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KYSE-450	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LiSWlEPTB;OD64OlU1QCEQvF2=	NHjPOm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
RMG-I	M3S0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn4Xo5VUUN3ME25MlE1ODV6IN88US=>	NWTQN\|FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CAKI-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37BVmlEPTB;OT6zNVk4QSEQvF2=	NG[3VIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KYSE-510	NGHsSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7V[WVpUUN3ME25MlM2Pzd6IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A4-Fuk	NIOxfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzITWM2OD17LkO2O\|AyKM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
AN3-CA	NXrKcmJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofYTWM2OD17LkS1OFQ1KM7:TR?=	NG\lfoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SK-N-DZ	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTlwN{K4OFkh\|ryP	M1\MelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HSC-2	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O3c2lEPTB;OT63OlYzQSEQvF2=	NVrx[JJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
EW-1	M2HoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk[xTWM2OD17Lke5N\|Y6KM7:TR?=	MnfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
D-566MG	M3HXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTlwOEO2OlQh\|ryP	MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
COLO-792	NWnCeHc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTlwOUi3OFYh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TE-10	M{f4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTFyLkCzPVYh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H650	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTFyLkSyPFYh\|ryP	M1TY[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
U-266	NXfYNI4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jrWGlEPTB;MUCuOFU2KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
Detroit562	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkiyTWM2OD1zMT6wOVE2KM7:TR?=	NGHtZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NH-12	M3\Sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXiwO2NWUUN3ME2xNU4yPDR4IN88US=>	NXPM[Zp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
CO-314	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfPbXl6UUN3ME2xNU4zQDR{IN88US=>	NF;ZV3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
IST-MEL1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrUVoxKSzVyPUGxMlU{OjNizszN	NEDXdZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KNS-81-FD	NXT3bIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHruZVdKSzVyPUGxMlU2OjdizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW1463	NXnSclhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjFbGdKSzVyPUGxMlU6QDlizszN	NVXaZoFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H23	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\6Z45KSzVyPUGxMlY2PTJizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-MEL-2	M1Lmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTFzLkexPVch\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmmzTWM2OD1zMj6xOFk2KM7:TR?=	MnK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
Daoy	M4rPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXxTVJKSzVyPUGyMlI5PTZizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H1623	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHK1XWxKSzVyPUGyMlM5ODFizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NMC-G1	M{LaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzKUYVYUUN3ME2xNk44OTdizszN	NEDndoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
DK-MG	NVLkN3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHETWM2OD1zMj65OFgzKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
TCCSUP	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TFZ2lEPTB;MUOuNVI5PCEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SCC-15	M3fROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvHPIFmUUN3ME2xN{4zPjVzIN88US=>	NUfTeI5xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NOS-1	NHHIPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzPWlJKSzVyPUGzMlI5QTNizszN	MoOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RH-1	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTF\|LkOwN\|ch\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SK-MEL-3	Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\KRmlEPTB;MUOuN\|czQCEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NB5	NXHBNJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkexTWM2OD1zMz60NFY4KM7:TR?=	M4j1WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SNU-387	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfhcW9DUUN3ME2xN{42ODd{IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
CAL-120	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrFeXNKSzVyPUGzMlY4OThizszN	NWL1XHNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
Mo-T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrQTWM2OD1zMz63NFch\|ryP	M4[2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LNCaP-Clone-FGC	NGrafodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\5TWM2OD1zMz63PVkzKM7:TR?=	Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CAN	NET2OlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\0blNKSzVyPUG0MlAzQDhizszN	NVK2OpBrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
SK-MEL-30	NYLVWpNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmG3TWM2OD1zND6wOlMh\|ryP	NGTmd5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
COLO-678	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTF2LkC4NlIh\|ryP	NIjXdJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SCC-9	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF2LkGwNlEh\|ryP	NEfEfo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
KINGS-1	NWKzSll5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF2LkG0NFIh\|ryP	NFrEbZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SL-513	MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LPdmlEPTB;MUSuNVg4KM7:TR?=	NHG1Wm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HLE	M1vRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF2LkO4OVIh\|ryP	NIexZ4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SW1573	NETNdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzNUVRKSzVyPUG0MlQ1OzVizszN	NV\HcFVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KYSE-140	M1jrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF2Lk[zNlch\|ryP	MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SK-PN-DW	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrHbIZKSzVyPUG0MlgxODFizszN	MmjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
A253	NYHHZY16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvKTWM2OD1zNT6wOlI2KM7:TR?=	NGH1SIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CAL-12T	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX2zXYN[UUN3ME2xOU41PjZ{IN88US=>	NUnzNXd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
COLO-679	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPlSmNrUUN3ME2xOU44Pjh\|IN88US=>	M1rhTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
UACC-257	NFzSS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTTTWM2OD1zNj6xNlAyKM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
U-87-MG	NF3BcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCxTWM2OD1zNj6zOVI{KM7:TR?=	NGn5dY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HCC1806	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\ITWM2OD1zNj63NFcyKM7:TR?=	M1rsRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H2170	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjocYxiUUN3ME2xO{4zPDR6IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
AGS	NEC3b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF5LkO4NFgh\|ryP	MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
MEL-HO	NWPjVVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknFTWM2OD1zNz63OVA{KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SW48	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFm3U4FKSzVyPUG3Mlc4OTZizszN	NILYZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HuP-T4	NFfWenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7RPVVKSzVyPUG4MlAzODZizszN	M2PBV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H720	NVHaZXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTF6LkG0NFIh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
RCC10RGB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF6LkG2PVch\|ryP	NILZR5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HD-MY-Z	NYHX[ZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTNZY9KSzVyPUG4MlIzPTRizszN	NGW2[ok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
A427	NFfSZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTj[ZhKSzVyPUG4MlUxQTRizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HCC2998	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHWZpR{UUN3ME2xPE43ODVzIN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
EPLC-272H	NW[2fW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;nTWM2OD1zOT6wOFM1KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
C32	NEPiWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTF7LkC0OUDPxE1?	M1LrXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
UMC-11	NHXhT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{WwZWlEPTB;MUmuNlEzOyEQvF2=	NIHLeIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CaR-1	NXXFcpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonCTWM2OD1zOT62PFA1KM7:TR?=	M{XMPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
KYSE-410	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTaTWM2OD1zOT65NVM6KM7:TR?=	M{\IRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HuCCT1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnkcJhPUUN3ME2yNE43Ojl2IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LB996-RCC	NFfUXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGT1OolKSzVyPUKwMlcyPjhizszN	NW\nTW9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
KYSE-70	NEe4Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFP4SW5KSzVyPUKwMlgxPTlizszN	NE\UVHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
CAL-72	NIO5NHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJyLkmxOUDPxE1?	NFfjbY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
Capan-2	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWmzPZBsUUN3ME2yNU4xPDF\|IN88US=>	NUPQR5N{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
PANC-08-13	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTJzLkK1NVUh\|ryP	MkK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
SBC-1	NVvQTGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Wz[2lEPTB;MkGuN\|A5OSEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MFM-223	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJzLkOzOFIh\|ryP	NHrlcVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
BB49-HNC	NVvpNFZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnPTWM2OD1{MT61O\|E3KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SH-4	NF\DPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DGfGlEPTB;MkGuOlYyQCEQvF2=	M2fxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HuO9	NV;3T5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzJTWM2OD1{MT65PFI2KM7:TR?=	M3rKOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
AM-38	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3S1b2lEPTB;MkKuNFQ5PSEQvF2=	NYf5XY9XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A431	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJ\|LkKxNVkh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
YAPC	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;DUWlEPTB;MkOuNlY2OSEQvF2=	M4XMXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
LU-139	M3;GSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rzOGlEPTB;MkOuOFgxQSEQvF2=	Mn3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HEC-1	M1zzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorWTWM2OD1{Mz60PVM4KM7:TR?=	NGr6eG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
SCC-25	NX;rNI52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPCbnZKSzVyPUK0MlMxODZizszN	MlTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
HT-29	M{CzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7wTWM2OD1{ND6zPFI{KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
PC-14	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTJ2Lk[1O\|Eh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
Calu-6	NFrXN\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlX1TWM2OD1{NT61NFcyKM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
SJRH30	NILMNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3Jc25KSzVyPUK1MlY1QTZizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
ChaGo-K-1	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{H0[WlEPTB;Mk[uNVYzQSEQvF2=	MnPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
IA-LM	MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJ4LkO2OFUh\|ryP	NGjW[YI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
GP5d	NH\YRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[1TWM2OD1{Nj60OFkyKM7:TR?=	M4\QclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H2291	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJ4Lk[1OFEh\|ryP	NYq4O40{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
BALL-1	NEjaRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnqXGlXUUN3ME2yOk46Ozl5IN88US=>	NXXtOHZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
HCC1954	M{jQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorWTWM2OD1{Nj65PFA5KM7:TR?=	NG\5XlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H2452	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fCVmlEPTB;MkeuOFE3OyEQvF2=	NUL6ZZlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
LU-99A	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ5LkW1PFIh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NTERA-S-cl-D1	NGe4fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoKwTWM2OD1{Nz63Nlk6KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
PANC-10-05	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHwTWM2OD1{Nz63O\|c2KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2405	NFTWWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoC5TWM2OD1{Nz65N\|g4KM7:TR?=	M321c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-415	NH\QPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTJ6LkSxN\|ch\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2342	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXHT3NSUUN3ME2yPE42OjhzIN88US=>	NX30SXpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
TGBC24TKB	NH;YW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3yfWJKSzVyPUK4MlcyOTdizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LU-134-A	M3W0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\oc5pKSzVyPUK4MlkzPjFizszN	M{L1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
SCC-4	NYPFRVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zwbWlEPTB;M{GuNFQ6PCEQvF2=	M1vGXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
Saos-2	NH:2eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWizeIU{UUN3ME2zNU46OzB4IN88US=>	Mnj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
RERF-LC-MS	MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlW5TWM2OD1\|Mj64NlMyKM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
M14	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLYTWM2OD1\|Mj65O\|Y1KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
HPAF-II	M{joSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmryTWM2OD1\|Mz61NFEyKM7:TR?=	MmXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1755	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTN2LkOzNFUh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
D-392MG	NEPpV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1H4RWlEPTB;M{WuPFY4PCEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
A704	NGLpTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XOZWlEPTB;M{[uNFQzPyEQvF2=	Ml;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
CP50-MEL-B	NGXGVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TTR2lEPTB;M{[uNVkyOSEQvF2=	Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
EW-18	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUP6O2Y5UUN3ME2zOk41PTJizszN	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
WM-115	NVmyfXhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjwUI9KSzVyPUO2MlgxQTlizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
LU-65	M1:5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jYZWlEPTB;M{euNVQyPyEQvF2=	NXzpSVJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
NCI-H1563	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHO3d\|BKSzVyPUO3MlI1QDRizszN	NHXpR5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
DBTRG-05MG	M3LyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUT4XXV1UUN3ME2zPE4xPjlzIN88US=>	NELBZpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
NCI-H630	M3WyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrMTW5KSzVyPUO4MlQ4OTRizszN	M3PYbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1155	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\jTmlEPTB;M{muNlQzKM7:TR?=	NVfrRlZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
OVACR-3	NYLTU5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MliwTWM2OD1\|OT65NVk2KM7:TR?=	M1zBRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OAW-42	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;RTWM2OD12MD60NlU5KM7:TR?=	Ml\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6QTZ\|Lze+V2FPT0WUPD;hQi=>
JVM-2	NV3GWItuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Tw[GlEPTB;NEGuNlQyPSEQvF2=	NXeyfnBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
C3A	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoL2TWM2OD12MT6zOFQ4KM7:TR?=	M2XE[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
HT55	M3XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTR{LkK4OFEh\|ryP	M3fhNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
OVCAR-4	NXTQWXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3qTWM2OD12Mj6yPVc1KM7:TR?=	NW\vcm9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
MEG-01	NG[yUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D3V2lEPTB;NEKuOFYyPiEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H82	M2fSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTR\|Lkm4PVIh\|ryP	M{X6ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
JEG-3	MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4ezd2lEPTB;NESuPVQ4KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
BPH-1	M{XPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;NTWM2OD12Nj6zPVk5KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
MPP-89	M1fCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XsTGlEPTB;NEeuNlg6QCEQvF2=	NX;kRVZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
ALL-PO	NWm2bZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLrOGhKSzVyPUS3MlQyQDhizszN	NEPzTo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl7NkOvK\|5USU6JRWK8M4E,
HT	NFP3d3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPKTWM2OD12Nz60PVIh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
NCI-H2347	NGjsNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLSTWM2OD12OD6wO\|E2KM7:TR?=	NUTEcWR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7OU[zM{c,W0GQR1XSQE9iRg>?
A2780	NGjEOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPKXm5KSzVyPUS5MlQzOjhizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+
KARPAS-299	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTR7LkWxNVkh\|ryP	M3fxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTl4Mz:nQnNCVkeHUkyvZV4>
NCI-H1651	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTR7Lki4NlEh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk6PjNxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04841148	Not yet recruiting	Drug: HCQ\|Drug: Avelumab\|Drug: Palbociclib	Breast Cancer	Abramson Cancer Center of the University of Pennsylvania\|Johns Hopkins University\|Translational Breast Cancer Research Consortium\|Pfizer\|Breast Cancer Research Foundation	May 2021	Phase 2
NCT04669587	Recruiting	Drug: ZB716\|Drug: Palbociclib	Estrogen Receptor-Positive\|HER2-Negative\|Locally Advanced Breast Cancer\|Metastatic Breast Cancer	EnhancedBio USA Inc.\|Zenopharm LLC\|EnhancedBio Inc.	May 10 2021	Phase 1\|Phase 2
NCT04735367	Not yet recruiting	Drug: palbociclib plus letrozole	Breast Cancer	Pfizer	February 1 2021	--
NCT04654208	Recruiting	Drug: palbociclib	Malignant Neoplasm of Breast	Pfizer	December 15 2020	--
NCT04671615	Recruiting	Drug: palbociclib	Metastatic Breast Cancer	Pfizer	December 6 2020	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol (L86-8275) HCl

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (CYC202)

Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl